Skip to main content

Table 1 Patient characteristics

From: Patient-reported outcomes following stereotactic body radiation therapy for clinically localized prostate cancer

  

Patients (N = 228)

Age (y/o)

(Median = 69)

 
 

Age ≤ 60

11.0%

 

60 < Ages ≤ 70

45.6%

 

Age > 70

43.4%

Race

  
 

White

58.8%

 

Black

35.5%

 

Other

5.7%

Partner status

  
 

Yes

75.40%

 

No

24.60%

Employment status

  
 

Yes

47.40%

 

No

52.60%

Median pre-treatment PSA (ng/mL)

 

6.1 (1.3-32.5) ng/dL

Median pre-treatment Testosterone (nmol/L)

 

11 (3.99-39.87) nmol/L

Risk groups (D’Amico’s)

  
 

Low risk

38.6%

 

Intermediate risk

55.3%

 

High risk

6.1%

Sexual aid

  
 

None

61.9%

 

Yes (Any)

38.1%

SBRT dose

  
 

36.25 Gy

84.2%

 

35 Gy

13.2%

 

Other

2.6%